XOMA Disclosed It Had Received An $8.1M Milestone Payment From Viracta Therapeutics, Inc., Related To Day One Biopharmaceuticals' Recent Sale Of Its Priority Review Voucher (Prv) For $108MTo An Undisclosed Buyer
XOMA Disclosed It Had Received An $8.1M Milestone Payment From Viracta Therapeutics, Inc., Related To Day One Biopharmaceuticals' Recent Sale Of Its Priority Review Voucher (Prv) For $108MTo An Undisclosed Buyer
XOMA透露，與Viracta Therapeutics公司相關，該公司已收到810萬美元的里程碑付款，與Day One生物製藥最近出售其優先審查券（PRV）有關。價值1.08億美元，買家未透露。
XOMA Disclosed It Had Received An $8.1M Milestone Payment From Viracta Therapeutics, Inc., Related To Day One Biopharmaceuticals' Recent Sale Of Its Priority Review Voucher (Prv) For $108MTo An Undisclosed Buyer
XOMA透露，與Viracta Therapeutics公司相關，該公司已收到810萬美元的里程碑付款，與Day One生物製藥最近出售其優先審查券（PRV）有關。價值1.08億美元，買家未透露。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。